Changes in Hong Kong stocks | Jietai Technology-P (07666) rose nearly 11% in the intraday MTS-128 Global License Agreement has reached a “platform+product” to open up long-term growth logic

The Zhitong Finance App learned that Jetai Technology-P (07666) rose nearly 11% in the intraday period. As of press release, it rose 6.2% to HK$11.3, with a turnover of HK$2019 million.

According to the news, at the end of June this year, Jietai Technology announced that it had reached an exclusive MTS-128 global licensing agreement with Boulevard, a subsidiary of Deerfield Management. The company received a down payment of 20 million US dollars, a milestone payment of up to 1.6 billion US dollars and a potential sales share. It is currently the largest licensing transaction for the pre-clinical TCE project in China. Dr. Lai Caida, co-founder, chairman and CEO of Jietai Technology, recently said that the dividend period for AI for Science has just begun, and the future will usher in a bigger explosion. As far as the company is concerned, it will continue to focus on global cooperation between platform IP and pipeline IP in the short term, and will continue to explore various business cooperation models such as License, NewCo, and Co-development in the future.

Shen Wan Hongyuan pointed out that the company relies on an AI platform to establish a diversified pipeline matrix, and the “platform+product” two-wheel drive opens up a long-term growth logic. In terms of business model, the company uses “platform+product” two-wheel drive: platform cooperation provides partners with LNP formulation discovery, small molecule formulation optimization, and mRNA sequence design services, etc., and has established more than 30 partnerships; product cooperation integrates delivery systems with its own payloads, and flexibly selects independent development or external licensing. Significant flywheel collaboration has formed between the two models. External cooperation data flows back into the platform iteration, and platform upgrades continue to enhance R&D capabilities and competitiveness.